Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT04339543 Terminated - Parkinson Disease Clinical Trials

Longitudinal Analysis of Gait Variability to Predict Falls in Parkinson's Disease

Start date: February 28, 2020
Phase: N/A
Study type: Interventional

The broad goal of this research project is to improve the prediction of falls in patients with Parkinson's disease (PD) through a comprehensive multidisciplinary approach that includes longitudinal measurements of walking, cognitive and functional performances. PD is a life-changing disorders affecting one million Americans, with more than 60,000 new cases reported every year. Within 3 years of diagnosis, more than 85% of people with clinically probable PD develop gait problems, which in turn lead to falls resulting in serious injury and reduced quality of life. There is a pressing need to identify fall risk factors before the occurrence of the first fall, and to better understand behavioral and cognitive changes leading to falls in PD patients.

NCT ID: NCT04322227 Terminated - Healthy Clinical Trials

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Start date: January 23, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate effects of foliglurax on brain wave patterns (electric signals) in healthy subjects and in patients with PD

NCT ID: NCT04291027 Terminated - Parkinson Disease Clinical Trials

Aquatic Group Exercise for People With Parkinson Disease

Start date: February 28, 2020
Phase: N/A
Study type: Interventional

This study will investigate the impact of land based or aquatic based group exercise on the balance, walking, balance confidence, and quality of life of people with idiopathic Parkinson disease. Participants will be randomized to participate in a land based or aquatic based group exercise program 2 times per week for 12 weeks. Prior to and after participation, balance, walking, quality of life, and balance confidence will be measured by a blinded examiner.

NCT ID: NCT04275492 Terminated - Parkinson's Disease Clinical Trials

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets

PLKS-BE
Start date: July 24, 2020
Phase: N/A
Study type: Interventional

The main purpose of In two kinds of fasting and postprandial Chinese healthy subjects with Boehringer represent Ingelheim company production of hydrochloric acid Pramipexole zyban (specification: 0.26 mg/piece, in Pramipexole, commodity name: Siforl ®) as the reference preparation, study a single oral dose of macro crown biological pharmaceutical co., LTD. Production of Pramipexole Dihydrochloride Sustained Release Tablets (specification:The pharmacokinetic parameters of the drug were calculated after the time course of the drug in vivo (0.375mg/ tablet, as measured by pramipexole hydrochloride), and the human relative bioavailability of the two preparations were compared to evaluate their bioequivalence. A secondary purpose To evaluate the safety of fasting and postprandial oral test preparations and reference preparations.

NCT ID: NCT04183634 Terminated - Parkinson Disease Clinical Trials

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Start date: December 3, 2019
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the adhesion of the test product when compared to the reference product following a single transdermal application.

NCT ID: NCT04175132 Terminated - Healthy Clinical Trials

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

Start date: November 12, 2019
Phase: Phase 1
Study type: Interventional

A study to learn how foliglurax binds in regions of the brain

NCT ID: NCT04164758 Terminated - Parkinson's Disease Clinical Trials

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Start date: October 23, 2019
Phase: Phase 2
Study type: Interventional

This is a pilot study to explore the effects of pimavanserin and low-dose quetiapine in subjects with Parkinson's disease with neuropsychiatric symptoms.

NCT ID: NCT04164043 Terminated - Parkinson's Disease Clinical Trials

Efficacy of a Recreation Therapy Wellness Recovery Program for Individuals With Parkinson's Disease

Start date: March 6, 2018
Phase: N/A
Study type: Interventional

The Recreation Therapy Wellness Recovery Program conducts group classes which provide repetitive training of foundational skills designed specifically for those with Parkinson's Disease. The course will encourage bigger and faster movements (adapted from the Parkinson Wellness Recovery, PWR!Moves ® program) and education on optimal function.

NCT ID: NCT04119596 Terminated - Parkinson Disease Clinical Trials

Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease

Start date: September 1, 2020
Phase:
Study type: Observational

A case-control study to identify microbiome and genetic differences between healthy subjects and patients with incident Parkinson's disease.

NCT ID: NCT04054856 Terminated - Parkinson Disease Clinical Trials

Sensor-supported Classification of Gait Patterns in Everyday Movement of Patients With Parkinson's Disease

PD-GPC
Start date: December 16, 2019
Phase: N/A
Study type: Interventional

Within this study we conduct long-term measurements on Parkinson patients using a three sensor IMU setup: one sensor is located at the wrist, one sensor at the belt/ in the pocket and one sensor is worn as a pendant. Before and after each long-term measurement phase (5 days within 6-8 weeks) we perform an UPDRS to identify changes in everyday life behaviour that correlate with UPDRS trends (especially part 3).